Drug intelligence / Profile preview

Enprostil

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Enprostil is a synthetic analog of prostaglandin E2 (PGE2) developed for the treatment and prevention of peptic ulcers and gastroduodenal ulcers. It acts primarily as an agonist at the prostaglandin E2 EP3 receptor on gastric mucosal cells, leading to potent inhibition of gastric acid secretion and providing mucosal protection. Unlike natural PGE2—which activates all four EP receptors—enprostil’s selectivity for EP3 may reduce unwanted side effects associated with broader prostaglandin activity. The drug has demonstrated efficacy in healing duodenal and gastric ulcers comparable to H2 antagonists such as cimetidine or ranitidine[1][3][4][5][6].

Brand names: Camleed
Other names: EnprostiloEnprostilum

Targets

PTGER3 (Prostaglandin E2 receptor EP3 subtype)

Beyond the preview

Go deeper on Enprostil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enprostil.

Explore the full profile